Heartseed

Heartseed EBITDA per Share

The EBITDA per Share of Heartseed (219A.T) as of Nov 22, 2026 is 10.16 JPY. In the previous year, EBITDA per Share was -46.40 JPY — a change of -121.90% (higher).

EBITDA per Share

10.16JPY

YoY

-121.90%

Last updated:

EBITDA per Share of Heartseed is 2025 10.16 JPY. EBITDA per Share of Heartseed was 2024 -46.40 JPY. It decreases by -121.90% higher compared to the previous year.

The Heartseed EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2022
-63.61 JPY
Jan 1, 2023
-63.62 JPY
Jan 1, 2024
-46.40 JPY
Jan 1, 2025
10.16 JPY
The Heartseed EBITDA per Share history
YEAREBITDA per ShareYoY
10.16JPY-121.90%
-46.40JPY-27.07%
-63.62JPY+0.01%
-63.61JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Heartseed Stock analysis

What does Heartseed do? Heartseed Inc generates revenue through the development and commercialization of regenerative medicine products, primarily focusing on cardiac therapies. The company's leading product HS-001 involves administering regenerated myocardium derived from allogeneic iPS cells to treat severe heart failure in patients with dilated cardiomyopathy (DCM), old myocardial infarction (OMI), and dilated-phase hypertrophic cardiomyopathy (D-HCM). Heartseed also researches autologous iPS cell-based myocardium creation to avoid immune rejection and explores HLA knockout iPS cells for future applications. Revenue streams include clinical trial partnerships, potential licensing agreements, and future product sales once regulatory approvals are secured. The primary customers for Heartseed's therapies are patients with severe heart failure suffering from DCM, OMI, and D-HCM, as well as healthcare providers and hospitals specializing in cardiology. The company targets the Japanese market initially, leveraging its headquarters in Minato-Ku, Tokyo-To, and its focus on cardiac regenerative medicine. Heartseed's research pipeline includes both allogeneic and autologous iPS cell therapies, with HS-001 positioned as the flagship product for immediate commercialization. Heartseed Inc's business model relies on advancing its pipeline through clinical trials and securing regulatory approvals for HS-001 and other therapies. The company's revenue will likely come from product sales once approved, with potential early-stage income from research collaborations. The focus remains on cardiac regenerative medicine, particularly for heart failure conditions, with no mention of other therapeutic areas or market segments beyond the specified diseases. Heartseed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Heartseed stock

EBITDA per Share of Heartseed is 10.16 JPY in 2025.

EBITDA per Share of Heartseed changed from -46.40 JPY to 10.16 JPY, representing a -121.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Heartseed since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Heartseed

All Key Metrics — Heartseed